Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 387

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 387
---
, PhD
Dr. Baek has extensive clinical experience, combined with a track record of successfully leading impactful studies in colorectal and rectal cancer. Since March 2024, Dr. Baek has been a clinical professor at Korea University Guro Hospital. From 2009 to 2024, Dr. Baek was a research medical oncologist at National Cancer Center, Republic of Korea. From 2018 to 2019, she was a visiting investigator at Dana-Farber Cancer Center. Dr. Baek received her MD, MS and PhD at The Catholic University of Korea. Dr. Baek was selected to serve as a director due to her extensive medical experience.

#### Family Relationships
There are no family relationships among any of ParentCo’s directors or executive officers.

#### Corporate Governance

#### Composition of the ParentCo Board
ParentCo’s business and affairs will be organized under the direction of its board of directors. Chris Kim will serve as Chair of the Board. The primary responsibilities of the ParentCo Board will be to provide oversight, strategic guidance, counseling and direction to ParentCo’s management. The ParentCo Board will meet on a regular basis and additionally as required.

In accordance with the terms of the ParentCo Bylaws, which will be effective upon the consummation of the Business Combination, the ParentCo Board may establish the authorized number of directors from time to time by resolution. The ParentCo Board will consist of three (3) members upon the consummation of the Business Combination. In accordance with the ParentCo Certificate of Incorporation, which will be effective upon the consummation of the Business Combination, the ParentCo Board will be divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. ParentCo’s directors will be divided among the three classes as follows:

•

the Class I director will be Mr. Nicholas Fernandez and Dr. Ji Yeon Baek, with a term that will expire at the annual meeting of stockholders to be held in 2026;

•

the Class II director will be Dr. Eun Sook Lee, with a term that will expire at the annual meeting of stockholders to be held in 2027; and

•

the Class III director will be Mr. Chris Kim, with a term that will expire at the annual meeting of stockholders to be held in 2028.

Any additional director